Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0) has announced the appointments of Zachary T. Stadnyk to its Board of Directors and Natalia L. Butterworth as Corporate Secretary, effective immediately. The clinical-stage oncology company is advancing its capital markets strategy, including preparations for a Nasdaq listing.
Mr. Stadnyk, a former TSX Life Sciences Lead and biotech capital markets executive with over 15 years of experience, has led and supported over $100 million in institutional financings and contributed to strategic transactions such as the $435 million acquisition of The Supreme Cannabis Company by Canopy Growth. His expertise in public market execution and biotech advisory is expected to bolster Helix’s financing efforts.
Ms. Butterworth brings over 15 years of experience in governance and regulatory compliance across multiple jurisdictions. Based in British Columbia, she will support Helix’s compliance and corporate secretarial functions as the company scales its operations.
The appointments come as Helix finalizes the clinical protocol for its lead candidate, L-DOS47, and actively prepares for an uplisting to the Nasdaq through the Multijurisdictional Disclosure System (MJDS). The company is also relocating its registered office from Toronto to Vancouver, British Columbia, to strengthen governance and capital markets infrastructure.
“As Helix continues to execute on its corporate and clinical development objectives, strengthening our capital markets and governance capabilities remains a key priority,” said Thomas Mehrling, MD, PhD, Chief Executive Officer of Helix BioPharma. “Zach brings a wealth of experience across biotechnology financing, public markets and strategic transactions, while Natalia adds strong governance and corporate secretarial expertise. These appointments come at an important time for Helix as we finalize the clinical protocol for L-DOS47 and actively prepare for a Nasdaq listing under the MJDS, including ongoing audit, governance, and capital markets readiness initiatives.”
Zachary Stadnyk commented, “I am excited to join Helix at such a pivotal stage in its development. The Company’s differentiated approach to addressing the tumor microenvironment and its clear path toward a Nasdaq listing creates a compelling opportunity. I look forward to supporting the team in advancing its capital markets strategy and unlocking value for its shareholders.”
The appointments signal Helix’s commitment to enhancing its board and governance structure, which is critical for attracting institutional investors and meeting the requirements of a major exchange like Nasdaq. The company’s pipeline is led by Tumor Defense Breaker L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its foundation with next-generation bi-specific antibody-drug conjugates in discovery.
Helix also advances two pre-IND candidates: LEUMUNA, an oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA, a first-in-class oral gemcitabine prodrug with bioavailability comparable to IV administration. The company is listed on the TSX, OTC PINK, and Frankfurt Stock Exchange. More information is available at https://www.helixbiopharma.com/.
This announcement reflects Helix’s strategic focus on strengthening its financial and governance foundation to support clinical development and potential value creation for shareholders as it approaches a Nasdaq listing.
